Picture of Vectus Biosystems logo

VBS Vectus Biosystems Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-15.54%
3m-20.28%
6m-34.08%
1yr-53.76%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-60.77%
50d MA-16.34%
200d MA-56.95%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-159.11%
Return on Equity-69.1%
Operating Margin-4418.45%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Vectus Biosystems EPS forecast chart

Profile Summary

Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
December 12th, 2005
Public Since
February 23rd, 2016
No. of Shareholders
601
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
53,209,361

VBS Share Price Performance

Upcoming Events for VBS

Full Year 2024 Vectus Biosystems Ltd Earnings Release

Similar to VBS

Picture of Actinogen Medical logo

Actinogen Medical

au flag iconAustralian Stock Exchange - SEATS

Picture of Adalta logo

Adalta

au flag iconAustralian Stock Exchange - SEATS

Picture of Algorae Pharmaceuticals logo

Algorae Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Alterity Therapeutics logo

Alterity Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Amplia Therapeutics logo

Amplia Therapeutics

au flag iconAustralian Stock Exchange - SEATS

FAQ